Literature DB >> 2502505

T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer.

C H Snyderman1, D S Heo, K Chen, T L Whiteside, J T Johnson.   

Abstract

Fresh suspensions of tumor-infiltrating lymphocytes (TIL) from 16 patients with squamous cell carcinoma of the head and neck (SCCHN) were examined for T-cell markers including CD4 (helper-inducer), CD8 (cytotoxic-suppressor), natural killer (NK) cell, and activation surface markers using monoclonal antibodies and two-color flow cytometry. Two of 8 (25%) patients with a CD4/CD8 ratio of less than 1 developed cervical lymph node metastases; none had extracapsular spread. Six of 8 (75%) patients with a CD4/CD8 ratio of greater than 1 developed cervical metastases; 5 of 6 (83%) exhibited extracapsular spread. An increased CD4/CD8 ratio was attributable to a decrease in CD8+ cells. A CD4/CD8 ratio of greater than 1 may be a useful prognostic indicator of the development of cervical metastases.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2502505     DOI： 10.1002/hed.2880110408

Source DB:  PubMed          Journal:  Head Neck        ISSN： 1043-3074            Impact factor:   3.147


  9 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

2.  The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC.

Authors:  C W Smith; Z Chen; G Dong; E Loukinova; M Y Pegram; L Nicholas-Figueroa; C Van Waes
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

3.  Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.

Authors:  Neil L Berinstein; Gregory T Wolf; Paul H Naylor; Lorraine Baltzer; James E Egan; Harvey J Brandwein; Theresa L Whiteside; Lynn C Goldstein; Adel El-Naggar; Cecile Badoual; Wolf-Herve Fridman; J Michael White; John W Hadden
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

4.  An autologous system for culturing head and neck squamous cell carcinomas for the assessment of cellular therapies on the chorioallantois membrane.

Authors:  S Gronau; B Thess; H Riechelmann; Y Fischer; A Schmitt; M Schmitt
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-10-27       Impact factor: 2.503

5.  In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumour-infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells.

Authors:  J Hald; N Rasmussen; M H Claesson
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

Review 6.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers.

Authors:  Ravindra Uppaluri; Gavin P Dunn; James S Lewis
Journal:  Cancer Immun       Date:  2008-12-04

7.  Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium.

Authors:  John S Yu; Paul K Lee; Moneeb Ehtesham; Ken Samoto; Keith L Black; Christopher J Wheeler
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

8.  Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck.

Authors:  J Hald; N Rasmussen; M H Claesson
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

9.  Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma.

Authors:  Won Jong Jin; Amy K Erbe; Ciara N Schwarz; Abigail A Jaquish; Bryce R Anderson; Raghava N Sriramaneni; Justin C Jagodinsky; Amber M Bates; Paul A Clark; Trang Le; Keng-Hsueh Lan; Yi Chen; KyungMann Kim; Zachary S Morris
Journal:  Front Immunol       Date:  2020-11-12       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.